News & Views
Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep
Jan 21 2021 Read 827 Times
Thermo Fisher Scientific Inc and Groupe Novasep SAS have announced that Thermo Fisher has completed the acquisition of Henogen SA, Novasep’s viral vector manufacturing business in Belgium for approximately €725 million in cash.
Novasep’s viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. With two locations in Seneffe and Gosselies, Belgium, Novasep’s viral vector business offers more than 7,000 m2 of state-of-the-art clinical and commercial manufacturing capacity. Founded more than 20 years ago, the business has approximately 400 employees with substantial operational and technical expertise in a broad range of viral vector classes and estimated 2020 revenue of €80 million (or approximately $95 million).
“Novasep’s viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally,” said Michel Lagarde, Executive Vice President of Thermo Fisher. “The addition of their manufacturing capabilities in Europe complements our four development and manufacturing sites in North America. In addition, they bring an incredibly talented team with more than two decades of experience across a broad range of viral vectors. The combination will benefit our global customers seeking support and capacity in the region as well as European customers bringing new medicines to patients inside and outside of Europe.”
Michel Spagnol, President and CEO of Novasep said: “Thermo Fisher is an outstanding partner for our viral vector business and its future development. Our diverse customer base will benefit from the combination of our viral vector services capabilities with the scale and capabilities of Thermo Fisher. Our talented employees will bring deep expertise to an organisation that shares our commitment to providing ground-breaking new medicines to patients.”
The business will be part of the Pharma Services business within the Laboratory Products and Services Segment.
In This Edition Articles - Expanding the Boundaries of Light Scattering for Macromolecules - Electrostatic Charges and Their Effects on Weighing - How the world’s most advanced analytical...
View all digital editions
Mar 03 2021 Guanghzou, China
Mar 08 2021 Virtual Event
Mar 22 2021 Digital event
Apr 14 2021 Tokyo, Japan
Apr 20 2021 Virtual event